Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 8Withdrawn 3Terminated 2

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Sarcoma 1

Conditions

Pancreatic Neoplasms 4Neoplasms 3Multiple Myeloma 3Sarcoma 2Neoplasms, Plasma Cell 2Fatigue 1Desmoplastic Small Round Cell Tumor 1Carcinoma 1Breast Neoplasms 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

Dexamethasone 45Bortezomib 19Lenalidomide 18Calcium Dobesilate 18Melphalan 16Cyclophosphamide 11pomalidomide 10daratumumab 9elotuzumab 8carfilzomib 8pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone acetate 6fludarabine 5dexamethasone 21-phosphate 5Filgrastim 5venetoclax 4selinexor 4auricularum 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Whole-Body Irradiation 3Vorinostat 3Nivolumab 3Mycophenolic Acid 3Leukapheresis 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Multiple Myeloma × Ascorbic Acid × Clear all
NCT01125449 2025-05-18

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

Situs Cancer Research Center

Phase 2 Withdrawn
Plasma cellSarcoma

Adenocarcinoma, Carcinoma, Multiple Myeloma, Sarcoma, Desmoplastic Small Round Cell Tumor

NCT00085345 2013-07-10

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00112879 2013-07-10

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡